A Novel Drug for Treatment of Necrotizing Soft-Tissue Infections: A Randomized Clinical Trial

IMPORTANCE Necrotizing soft-tissue infections (NSTI) have high morbidity and mortality rates despite aggressive surgical debridement and antibiotic therapy. AB103 is a peptide mimetic of the T-lymphocyte receptor, CD28. We hypothesized that AB103 will limit inflammatory responses to bacterial toxins...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	JAMA surgery 2014-06, Vol.149 (6), p.528-536
Hauptverfasser:	Bulger, Eileen M, Maier, Ronald V, Sperry, Jason, Joshi, Manjari, Henry, Sharon, Moore, Frederick A, Moldawer, Lyle L, Demetriades, Demetrios, Talving, Peep, Schreiber, Martin, Ham, Bruce, Cohen, Mitchell, Opal, Steven, Segalovich, Irit, Maislin, Greg, Kaempfer, Raymond, Shirvan, Anat
Format:	Artikel
Sprache:	eng
Schlagworte:	Adult Aged Aged, 80 and over CD28 Antigens - administration & dosage CD28 Antigens - therapeutic use Cytokines - analysis Debridement Double-Blind Method Female Humans Injections, Intravenous Male Middle Aged Necrosis Organ Dysfunction Scores Placebos Prospective Studies Soft Tissue Infections - drug therapy Treatment Outcome United States
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!